Cadila Healthcare which is a part of Zydus Cadila, has received an establishment inspection report (EIR) from USFDA for its formulation manufacturing facility at Pharma SEZ near Ahmedabad.

From January 16 to 24, 2017, the SEZ unit underwent USDFA audit.

The EIR shows the successful closure of the inspection points raised by the US drug regulator.

Read EquityPandit’s Technical Analysis on Nifty Pharma